A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993. (Q40596683)

21 September 2017

1 reference

title

A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993. (English)

1 reference

21 September 2017

Rolinson GN

1

1 reference

21 September 2017

publication date

1 October 1994

1 reference

21 September 2017

published in

Journal of Chemotherapy

1 reference

21 September 2017

volume

6

1 reference

21 September 2017

issue

5

1 reference

21 September 2017

page(s)

283-318

1 reference

Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Review of bacterial resistance--a challenge to the treatment of urinary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

THE IN VITRO PROTECTION OF PENICILLIN FROM INACTIVATION BY PENICILLINASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

SYNERGISTIC ACTIVITY OF PENICILLINS AGAINST PENICILLINASE-PRODUCING GRAM-NEGATIVE BACILLI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Circulation in Italy of beta-lactamase-producing strains within the major groups of bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

LY164846 in vitro antimicrobial activity testing, including disk diffusion susceptibility tests using 30-microgram disks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activities of Ro 19-5247 and Ro 15-8074, new oral cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro evaluation of tigemonam, a novel oral monobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activities of aztreonam, imipenem, and amoxycillin-clavulanate against ampicillin-resistant Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of LY163892 against pathogens isolated from pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in-vitro activity of a new oral carbacephem, LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro susceptibilities of common pediatric pathogens to LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of the new oral cephalosporin Bay v 3522 against aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of BAY v 3522, a new oral cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of BAY v 3522, a new cephalosporin for oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In-vitro bactericidal activity of four oral antibiotics against pathogens responsible for acute otitis media in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in-vitro activity of tigemonam, a new monobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antibacterial activity of the penicillins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Branhamella catarrhalis: antibiotic susceptibility and beta-lactamase production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Recurrent and penicillin V-resistant otitis media. A treatment study with amoxycillin/clavulanate and cefaclor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In Vitro Activity of Commonly Used Oral Antimicrobial Agents Against Community Isolates of Respiratorypathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of the new oral cephalosporin BMY-28100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of Bay y 3118, a new quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative activity of BRL 25.000 with amoxycillin against resistant clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Laboratory studies on coagulase-negative staphylococci from CAPD-associated peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

ACTIVITY OF AMPICILLIN IN VITRO COMPARED WITH OTHER ANTIBIOTICS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

THE ROLE OF PENICILLINASE IN DETERMINING NATURAL AND ACQUIRED RESISTANCE OF GRAM-NEGATIVE BACTERIA TO PENICILLINS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

The antibiotic sensitivity of bacteria isolated from the blood of patients in St Thomas' Hospital, 1969-1988.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antibiotic resistance of coliform bacilli in urinary infection acquired by women outside hospital. A 12-year survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antibiotic sensitivities of urinary pathogens, 1971-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Changing patterns of bacterial resistance in relation to prophylactic use of cephaloridine and therapeutic use of ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Sensitivity of Gram-negative bacilli to ampicillin after six years' clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antibiotic resistance in urinary bacteria isolated in central Scotland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Susceptibility of urinary pathogens in a Dublin teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Incidence of beta-lactamase production among out patient clinical isolates in Middle Eastern countries and their antibiotic susceptibilities. Middle Eastern Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in Vitro Activity of Augmentin Against Community and Hospital-Acquired Gram-Negative Bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Novel beta-lactamases in amoxycillin-resistant Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Resistance to beta-lactam/clavulanate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro antimicrobial activity of carumonam (Ro 17-2301) and its influence on the activity of other antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In-vitro activity and beta-lactamase stability of LY163892.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of U-76,252 (CS-807), a new oral cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In-vitro sensitivity of amoxicillin/clavulanic acid (Augmentin) to isolated beta-lactamases and in-vitro antibacterial activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

The in-vitro activity of two new quinolones: rufloxacin and MF 961

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

More extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antibiotic susceptibility of anaerobic bacteria in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activities of amoxicillin-clavulanic acid and imipenem against anaerobic bacteria isolated from community hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activity of cefmetazole, cefotetan, amoxicillin-clavulanic acid, and other antimicrobial agents against anaerobic bacteria from endometrial cultures of women with pelvic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Susceptibility of anaerobic bacteria to BAY v 3522

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

In vitro activities of three of the newer quinolones against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Current antimicrobial therapy of anaerobic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Beta-lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Antimicrobial susceptibility of anaerobic bacteria in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Susceptibilities of 540 anaerobic gram-negative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Beta-Lactamase Production and Resistance to Beta-Lactam Antibiotics in Nocardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Amoxycillin-clavulanic acid treatment of melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Beta-lactamase-producing, penicillin-resistant gonococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

Penicillinase-producing Gonococci in Liverpool

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1120009X.1994.11741165

10.1080/1120009X.1994.11741165

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference